Study design

prospective

Study time

2018.1-2021.1

Country

Italy

Object

Inclusion criteria were: histological diagnosis of adenocarcinoma, no distant metastases at clinical staging, RP as the chosen primary treatment option, estimated life-expectancy of ≥10 years. 

Inclusion criteria

Exclusion criteria were: androgen deprivation therapies, chemotherapies, pelvic radiation therapies or treatments with other agents that could influence prostate tumor growth

Sample size

413

Topic classification

Prediction，Sexual function

Keypoint

Independently to the surgical approach, operative time, more than blood loss at RP, represents a significant variable able to influence surgical margins status and post-operative erectile disfunction.

Year